ArticleLung India : official organ of Indian Chest Society2026
Evaluating lung transplant referral and listing in chronic respiratory disease: A single-center experience from a tertiary care centre in India.
Article in Lung India : official organ of Indian Chest Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with advanced chronic respiratory diseases experience severe functional limitation, limited therapeutic options, and high mortality risk. Lung transplantation (LTx) offers potential survival benefit in carefully selected candidates. However, Indian data describing the severity profile and eligibility of such patients are scarce. This study assessed the proportion and characteristics of patients meeting International Society for Heart and Lung Transplantation (ISHLT) referral and listing criteria, along with disease severity, contraindications, and risk factors.
methodsThis retrospective observational study included adults admitted between January 2020 and October 2023 with interstitial lung disease, chronic obstructive pulmonary disease, bronchiectasis, or pulmonary vascular disease. Eligibility for LTx was evaluated using 2021 ISHLT consensus criteria. Lung Allocation Score was calculated as per OPTN/UNOS guidelines. ISHLT-defined risk factors, substantially increased risk, and absolute contraindications were recorded.
resultsAmong 401 patients, 105 (26.2%) met referral and 97 (24.2%) listing criteria. Most demonstrated advanced physiological limitation (mean FVC 44.1% predicted; median ECOG 3). ILD was the leading indication among listing-eligible patients (48.6%), followed by COPD (32.4%) and bronchiectasis (18.1%). LAS was highest in ILD (mean 47.8). ISHLT-defined risk factors were present in 90.5% of referral-eligible patients, with 25.7% showing substantially increased risk and 32.4% absolute contraindications. Findings may overestimate eligibility and severity given the inclusion of only hospitalized patients, limiting broader generalizability to ambulatory patients.
conclusionA considerable proportion of hospitalized patients with advanced respiratory disease are LTx-eligible, though many have comorbidities or modifiable risks. Early referral and multidisciplinary optimization are essential to improve candidacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.